Glaukos Corporation Stock News

Glaukos Corporation (GKOS) CEO Tom Burns on Q4 2021 Results - Earnings Call Transcript

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced | February 22, 2022

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include: Net sales of $73.2 million in Q4 2021. Glaucoma net sales of $57.1 million and Corneal Health net sales of $16.2 million in Q4 2021. Gross margin of

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ: PODD ) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago quarter EPS of $0.17. The stock has a 52-week-high of $324.81 and a 52-week-low of $193.70. At the end of the last trading period, Insulet closed at $253.19. BTIG upgraded the previous rating for DexCom Inc (NASDAQ: DXCM ) from Neutral to Buy. DexCom earned $0.89 in the third quarter, compared to $0.94 in the year-ago quarter. The current stock performance of DexCom shows a 52-week-high of $659.45 and a 52-week-low of $318.45. Moreover, at the end of the last trading period, the closing price was at $435.67. For Glaukos Corp (NYSE: GKOS ), William Blair upgraded the previous rating of Market Perform to Outperform. For the third quarter, Glaukos had an EPS of $0.21, compared to year-ago quarter EPS of $0.09. The stock has a 52-week-high of $99.00 and a 52-week-low of $39.35. At the end of the last trading period, Glaukos closed at $52.90.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen, Inc. (NASDAQ: BIIB) shares

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS ) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductions in intraocular pressure (IOP) in a 36-month analysis. The iDose TR contains formulated travoprost, a prostaglandin analog to reduce IOP. 70% and 68% of subjects in the fast- and slow-release iDose TR Full story available on Benzinga.com

Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial re

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name Rencofilstat Hepion Pharmaceuticals, I